PMID- 19536107
OWN - NLM
STAT- MEDLINE
DCOM- 20090708
LR  - 20240109
IS  - 1474-1768 (Electronic)
IS  - 1474-175X (Linking)
VI  - 9
IP  - 7
DP  - 2009 Jul
TI  - Novel anticancer targets: revisiting ERBB2 and discovering ERBB3.
PG  - 463-75
LID - 10.1038/nrc2656 [doi]
AB  - Aberrant receptor expression or functioning of the epidermal growth factor 
      receptor (Erbb) family plays a crucial part in the development and evolution of 
      cancer. Inhibiting the signalling activity of individual receptors in this family 
      has advanced the treatment of a range of human cancers. In this Review we 
      re-evaluate the role of two important family members, ERBB2 (also known as HER2) 
      and ERBB3 (also known as HER3), and explore the mechanisms of action and 
      preclinical and clinical data for new therapies that target signalling through 
      these pivotal receptors. These new therapies include tyrosine kinase inhibitors, 
      antibody-chemotherapy conjugates, heat-shock protein inhibitors and antibodies 
      that interfere with the formation of ERBB2-ERBB3 dimers.
FAU - Baselga, Jose
AU  - Baselga J
AD  - Vall d'Hebron Institute of Oncology, Vall d'Hebron University Hospital, Passeig 
      Vall d'Hebron 119-129, Barcelona 08035, Spain. jbaselga@vhio.net
FAU - Swain, Sandra M
AU  - Swain SM
LA  - eng
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
PT  - Review
DEP - 20090618
PL  - England
TA  - Nat Rev Cancer
JT  - Nature reviews. Cancer
JID - 101124168
RN  - 0 (Antibodies, Monoclonal)
RN  - 0 (Antibodies, Monoclonal, Humanized)
RN  - 0 (HSP90 Heat-Shock Proteins)
RN  - 0 (Protein Kinase Inhibitors)
RN  - EC 2.7.1.- (Phosphatidylinositol 3-Kinases)
RN  - EC 2.7.10.1 (Receptor, ErbB-2)
RN  - EC 2.7.10.1 (Receptor, ErbB-3)
RN  - EC 2.7.11.1 (Proto-Oncogene Proteins c-akt)
RN  - K16AIQ8CTM (pertuzumab)
SB  - IM
MH  - Antibodies, Monoclonal/therapeutic use
MH  - Antibodies, Monoclonal, Humanized
MH  - Dimerization
MH  - Female
MH  - HSP90 Heat-Shock Proteins/antagonists & inhibitors
MH  - Humans
MH  - Male
MH  - Neoplasms/*drug therapy/etiology
MH  - Phosphatidylinositol 3-Kinases/physiology
MH  - Protein Kinase Inhibitors/*therapeutic use
MH  - Proto-Oncogene Proteins c-akt/physiology
MH  - Receptor, ErbB-2/*antagonists & inhibitors/chemistry/physiology
MH  - Receptor, ErbB-3/*antagonists & inhibitors/chemistry/physiology
MH  - Signal Transduction/physiology
RF  - 144
EDAT- 2009/06/19 09:00
MHDA- 2009/07/09 09:00
CRDT- 2009/06/19 09:00
PHST- 2009/06/19 09:00 [entrez]
PHST- 2009/06/19 09:00 [pubmed]
PHST- 2009/07/09 09:00 [medline]
AID - nrc2656 [pii]
AID - 10.1038/nrc2656 [doi]
PST - ppublish
SO  - Nat Rev Cancer. 2009 Jul;9(7):463-75. doi: 10.1038/nrc2656. Epub 2009 Jun 18.